Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">TG Therapeutics target raised to $26 at FBR & Co. due to increased confidence in the approval of TG-1101 (9.55 +4.20)FBR & Co. raises their TGTX tgt to $26 from $24. This morning, co announced positive top-line data from its Phase III GENUINE study of TG-1101 (ublituximab) plus ibrutinib. The study met its primary endpoint, with an overall response rate (ORR) of 80% in the combination of TG-1101 plus ibrutinib compared to ibrutinib alone in treated patients. Firm believes <strong>the top-line data from the study are highly compelling and look forward to the full data set, which co is targeting to present at a medical meeting in 1H17.</strong> Co plans to meet with the FDA to discuss the results and filing for accelerated approval in 2H17. If the discussions are positive, firm expects a Biologics License Application (BLA) filing for TG-1101 in 1H18.</td> </tr></table>"